Healthcare Global Enterprises Ltd
Fundamental Score
Healthcare Global Enterprises Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of HCG across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (16.59%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Strong Revenue Growth (16.86%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (15.22% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (17.79% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (19.34% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Cash Generation (₹571.13 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (63.78%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Risk Factors
9 factors identified
Below-Average Return on Equity (5.14%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.56%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 296.22x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Elevated Debt Levels (D/E: 1.92)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Weak Interest Coverage (1.24x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High Debt-to-Equity Ratio
Observation: Elevated financial risk due to high leverage.
Analysis: High debt levels may strain cash flows and increase financial risk during economic downturns.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Healthcare Global Enterprises Ltd
About HCG
Business Overview
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Company Details
Key Leadership
HCG Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Healthcare Global Enterprises Ltd (HCG)?
As of 13 Feb 2026, 10:05 am IST, Healthcare Global Enterprises Ltd (HCG) is currently trading at ₹582.30. The stock has a market capitalization of ₹10.47K (Cr).
Is HCG share price Overvalued or Undervalued?
HCG is currently trading at a P/E ratio of 296.22x, compared to the industry average of 52.84x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Healthcare Global Enterprises Ltd share price?
Key factors influencing HCG's price include its quarterly earnings growth (Sales Growth: 16.86%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Healthcare Global Enterprises Ltd a good stock for long-term investment?
Healthcare Global Enterprises Ltd shows a 5-year Profit Growth of 19.34% and an ROE of 5.14%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.92 before investing.
How does Healthcare Global Enterprises Ltd compare with its industry peers?
Healthcare Global Enterprises Ltd competes with major peers in the Hospital. Investors should compare HCG's P/E of 296.22x and ROE of 5.14% against the industry averages to determine its competitive standing.
What is the P/E ratio of HCG and what does it mean?
HCG has a P/E ratio of 296.22x compared to the industry average of 52.84x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹296 for every ₹1 of annual earnings.
How is HCG performing according to Bull Run's analysis?
HCG has a Bull Run fundamental score of 36.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does HCG belong to?
HCG operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Healthcare Global Enterprises Ltd.
What is Return on Equity (ROE) and why is it important for HCG?
HCG has an ROE of 5.14%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Healthcare Global Enterprises Ltd generates profits from shareholders' equity.
How is HCG's debt-to-equity ratio and what does it indicate?
HCG has a debt-to-equity ratio of 1.92, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is HCG's dividend yield and is it a good dividend stock?
HCG offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has HCG grown over the past 5 years?
HCG has achieved 5-year growth rates of: Sales Growth 15.22%, Profit Growth 19.34%, and EPS Growth 17.79%.
What is the promoter holding in HCG and why does it matter?
Promoters hold 63.78% of HCG shares, with 5.52% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is HCG's market capitalization category?
HCG has a market capitalization of ₹10474 crores, placing it in the Mid-cap category.
How volatile is HCG stock?
HCG has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for HCG?
HCG has a 52-week high of ₹N/A and low of ₹N/A.
What is HCG's operating profit margin trend?
HCG has a 5-year average Operating Profit Margin (OPM) of 16.59%, indicating the company's operational efficiency.
How is HCG's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 16.86% and YoY Profit Growth of -9.56%.
What is the institutional holding pattern in HCG?
HCG has FII holding of 3.59% and DII holding of 18.36%. Significant institutional holding often suggests professional confidence in the stock.